Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 2.72 g/t Au over 139.9 metres at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mainz Biomed NV MYNZ

Healthcare Medical Care
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.


NDAQ:MYNZ - Post by User

Mainz Biomed NV
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(33)
•••
  • SmartBull65X
Post by SmartBull65on Nov 29, 2024 9:26am
41 Views
Post# 36337220

BBBYQ: A Speculative Bet on Restructuring

BBBYQ: A Speculative Bet on RestructuringBed Bath & Beyond’s trading volume is surging, with whispers of restructuring fueling speculation. A 15% bounce is possible if investors see progress on this front. It’s a high-risk, high-reward story. On a different note, MYNZ’s strategic moves in diagnostics show how consistent execution can create long-term value, avoiding the volatility of speculative plays.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities